Lorcaserin in Obesity: Identification of CNS Targets Using fMRI

Trial Profile

Lorcaserin in Obesity: Identification of CNS Targets Using fMRI

Active, no longer recruiting
Phase of Trial: Phase IV

Latest Information Update: 02 Feb 2017

At a glance

  • Drugs Lorcaserin (Primary)
  • Indications Obesity
  • Focus Therapeutic Use
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 05 Jan 2017 Primary endpoints amended. Also, time frame for primary endpoint (fMRI (Functional changes in the brain)) changed from 1 year to 28 days.
    • 05 Jan 2017 Planned primary completion date changed from 1 Oct 2016 to 1 Oct 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top